GRG Health Competitive Intelligence (CI) Perspectives and Opinions, October 2022
The development : In October 2022, Dostarlimab met its primary endpoint of Objective Response Rate (ORR) in a head-to-head trial against...
top of page
GRG's Center For Experiential Learning
Search
bottom of page